GH Research (GHRS) Cash & Current Investments (2020 - 2026)
GH Research (GHRS) posted quarterly Cash & Current Investments of $246.3 million for Q4 2025, up 104.91% year-over-year from $120.2 million in Q4 2024, and down 1.36% quarter-over-quarter from $249.7 million in Q3 2025.
GH Research (GHRS) Cash & Current Investments (2020 - 2026) Analysis & Trends
GH Research's Cash & Current Investments history runs 6 years deep, the most recent figure standing at $246.3 million for Q4 2025.
- In Q4 2025, Cash & Current Investments rose 104.91% year-over-year to $246.3 million; the TTM figure through Dec 2025 stood at $246.3 million (up 104.91% YoY), while the FY2025 annual figure was $246.3 million, up 104.91% from the prior year.
- Cash & Current Investments for Q4 2025 stood at $246.3 million, down from $249.7 million in the prior quarter.
- The five-year high for Cash & Current Investments was $280.7 million in Q3 2021, with the low at $120.2 million in Q4 2024.
- The 5-year median for Cash & Current Investments is $206.1 million (2022), against an average of $200.6 million.
- The sharpest annual moves came in 2021 and 2023: Cash & Current Investments jumped 5535620.0% in 2021, then sank 44.76% in 2023.
- GH Research's Cash & Current Investments stood at $276.8 million in 2021, then tumbled by 40.04% to $166.0 million in 2022, then decreased by 19.23% to $134.0 million in 2023, then slipped by 10.34% to $120.2 million in 2024, then surged by 104.91% to $246.3 million in 2025.
- Business Quant data shows GHRS's Cash & Current Investments at $246.3 million in Q4 2025, $249.7 million in Q3 2025, and $253.9 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 836.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.16 Bn |
| 10 | GH Research | 2.02 Bn | 1.68 Bn | - | 345.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 345.10 Mn |
| Dec 31, 2025 | 246.25 Mn |
| Sep 30, 2025 | 249.65 Mn |
| Jun 30, 2025 | 253.87 Mn |
| Mar 31, 2025 | 257.51 Mn |
| Dec 31, 2024 | 120.18 Mn |
| Sep 30, 2024 | 122.58 Mn |
| Jun 30, 2024 | 129.10 Mn |
| Mar 31, 2024 | 128.83 Mn |
| Dec 31, 2023 | 134.04 Mn |
| Sep 30, 2023 | 141.93 Mn |
| Jun 30, 2023 | 151.62 Mn |
| Mar 31, 2023 | 159.14 Mn |
| Dec 31, 2022 | 165.96 Mn |
| Sep 30, 2022 | 256.94 Mn |
| Jun 30, 2022 | 265.38 Mn |
| Mar 31, 2022 | 270.75 Mn |
| Dec 31, 2021 | 276.79 Mn |
| Sep 30, 2021 | 280.75 Mn |
| Dec 31, 2020 | 5,000.00 |